The Estrogen Receptor: A Logical Target for the Prevention of Breast Cancer with Antiestrogens

Journal of Mammary Gland Biology and Neoplasia

Volumn 4, Issue 4, 1999, Pages 401-413

  Tonetti, Debra A ^a   Jordan, V Craig ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NW University Medical School ^*

Author keywords

Breast cancer; Estrogen receptor; Prevention; Raloxifene; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL; BREAST TUMOR; CLINICAL TRIAL; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; METABOLISM; REVIEW;

ANIMALS; BREAST NEOPLASMS; CLINICAL TRIALS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; RECEPTORS, ESTROGEN;

EID: 0033201635     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018722502034     Document Type: Article

References (106)

1. G. T. Beatson (1896). On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet ii:104-107; 162-167.
2. S. Boyd (1900). On oophorectomy in cancer of the breast. Brit. Med. J. ii:1161-1167.
3. M. P. Cole, C. T. A. Jones, and I. D. H. Todd (1971). A new antioestrogenic agent in late breast cancer. An early appraisal of ICI 46, 474. Brit. J. Cancer 25:270-275.
4. H. W. C. Ward (1973). Antioestrogenic therapy for breast cancer: A trial of tamoxifen at two dose levels. Brit. Med. J. ii:13-14.
5. E. V. Jensen and H. I. Jacobson (1962). Basic guides to the mechanism of estrogen action. Recent Prog. Horm. Res. 18:387-414.
6. E. V. Jensen, G. E. Block, S. Smith, K. Kyser, and E. R. DeSombre (1971). Estrogen receptors and breast cancer response to adrenalectomy. NCI Monographs 34:55-70.
7. V. C. Jordan and S. P. Robinson (1987). Species specific pharmacology of antiestrogens: Role of metabolism. Fed. Proc. 46:1870-1874.
8. V. C. Jordan, E. Phelps, and J. U. Lindgren (1987). Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res. Treat. 10:31-35.
9. M. M. Gottardis and V. C. Jordan (1987). The antitumor actions of keoxifene (raloxifene) and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. 47:4020-4024.
10. R. T. Turner, G. K. Wakley, K. S. Hannon, and N. H. Bell (1987). Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J. Bone Min. Res. 2:449-456.
11. S. Turken, E. Siris, D. Seldin, E. Flaster, G. Hyman, and R. Lindsay (1989). Effects of tamoxifen on spinal bone density in women with breast cancer. J. Natl. Cancer Inst. 81:1086-1088.
12. R. R. Love, R. B. Mazess, H. S. Barden, S. Epstein, P. A. Newcomb, V. C. Jordan, P. P. Carbone, D. L. DeMets (1992). Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med. 326:885-886.
13. S. Rossner and A. Wallgren (1984). Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 52:339-346.
14. R. R. Love, D. A. Wiebe, P. A. Newcomb, L. Cameron, H. Leventhal, V. C. Jordan, J. Feyzi, and D. L. DeMets (1991). Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann. Int. Med. 115:860-864.
15. L. J. Lerner, J. F. Holthaus, and C. R. Thompson (1958). A nonsteroidal estrogen antagonist 1-(p-2 diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl-ethanol. Endocrinology 63:295-318.
16. L. J. Lerner (1981). The first nonsteroidal antioestrogen-MER 25. In R. L. Sutherland and V. C. Jordan (eds.), Nonsteroidal Antioestrogens: Molecular Pharmacology and Antitumor Activity. Sydney, Academic Press, pp. 1-16.
17. M. J. K. Harper and A. L. Walpole (1967). A new derivative of triphenylethylene: Effect of on implantation and mode of action in rats. J. Reprod. Fertil. 13:101-119.
18. G. W. Duncan, S. C. Lyster, J. J. Clark, D. Lednicer (1963). Antifertility activities of two diphenyl-dihydronaphthalene derivatives. Proc. Soc. Expl. Biol. Med. 112:439-442.
19. M. R. Callantine, R. R. Humphrey, S. L. Lee, B. L. Windsor, N. H. Schottin, and O. P. O'Brien. (1966). Action of an estrogen antagonist on reproductive mechanisms in the rat. Endocrinology 79:153-167.
20. D. E. Holtkamp, S. C. Greslin, C. A. Root, and L. J. Lerner (1960). Gonadotropin inhibiting and antifecundity effects of chloramiphene. Proc. Soc. Expl. Biol. Med. 105:197-201.
21. V. C. Jordan and L. J. Dowse (1976). Tamoxifen as an antitumor agent: Effect on oestrogen binding. J. Endocrinol. 68:297-303.
22. L. Terenius (1971). Antiestrogen and breast cancer. Eur. J. Cancer 7:57-64.
23. E. R. DeSombre and L. Y. Arbogast (1974) Effect of the antiestrogen CI628 on the growth of rat mammary tumors. Cancer Res. 34:1971-1976.
24. M. E. Lippman, G. Bolan, and K. Huff (1976). The effects of estrogen and antiestrogens on hormone-responsive human breast cancer in long term tissue culture. Cancer Res. 36:4595-4601.
25. L. Terenius (1971) Structure-activity relationships of antioestrogens with regard to interaction with 17 β oestradiol in the mouse uterus and vagina. Acta Endocrinol. Suppl. 66:431-437.
26. S. D. Lyman, and V. C. Jordan (1986). Metabolism of nonsteroidal antiestrogens. In V. C. Jordan (ed.), Estrogen/Antiestrogen Action and Breast Cancer Therapy, Madison UW Press, pp. 191-219.
27. S. P. Robinson, S. M. Langan-Fahey, and V. C. Jordan (1989). Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eur. J. Cancer Clin. Oncol. 25:1769-1776.
28. A. S. Levenson, and V. C. Jordan (1997). MCF-7: The first estrogen responsive breast cancer cell line (Perspectives in Cancer Research). Cancer Res. 57:3071-3078.
29. C. K. Osborne, K. Hobbs, and G. M. Clark (1985). Effects of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 45:584-590.
30. P. G. Satyaswaroop, R. J. Zaino, and R. Mortel (1984). Estrogen-like effects of tamoxifen on endometrial carcinoma transplanted in nude mice. Cancer Res. 44:4006-4010.
31. M. M. Gottardis, S. P. Robinson, P. G. Satyaswaroop, and V. C. Jordan (1988). Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 48:812-815.
32. A. M. Brzozowski, A. C. W. Pike, Z. Dauter, R. E. Hubbard, T. Bonn, O. Engstrom, L. Ohman, G. L. Greene, J-A. Gustafsson, and M. Carlquist (1997). Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (London) 389:753-758.
33. V. C. Jordan (1984). Biochemical pharmacology of antiestrogen action. Pharm. Rev. 36:245-276.
34. D. Lednicer, S. C. Lyster, G. W. Duncan (1967). Mammalian antifertitity agents IV Basic 3,4 dihydronaphthalenes and 1,2,3,4-tetrahydro-1-naphthols. J. Med. Chem. 10:78-86.
35. E. R. Clark, and V. C. Jordan (1976). Oestrogenic, antioestrogenic and fertility properties of a series of compounds related to ethamoxytriphetol (MER25) Br. J. Pharmacol. 57: 487-493.
36. D. W. Robertson, J. A. Katzenellenbogen, J. R. Hayes, and B. S. Katzenellenbogen (1982). Antiestrogen basicity-activity relationships: A comparison of the estrogen receptor binding and uterotropic potencies of several; analogs of (Z)-1,2diphenyl-1-[4-[2-(dimethylamino)ethoxyphenyl]but-1-ene(tamoxifen, Nolvadex) having altered basicity. J. Med. Chem. 25:167-172.
37. V. C. Jordan, and B. Gosden (1982). Importance of the alkylamino-ethoxysid e chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus. Mol. Cell Endocrinol. 27:291-306.
38. D. M. Wolf and V. C. Jordan (1994). The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res. Treat. 31:129-138.
39. W. H. Catherino, D. M. Wolf, and V. C. Jordan (1995). A naturally occurring estrogen receptor mutation results in increased estrogencity for a tamoxifen analog. Mol. Endocrinol. 9:1053-1063.
40. A. S. Levenson, D. A. Tonetti, and V. C. Jordan (1998). The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor α mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor. Brit. J. Cancer 77:1812-1819.
41. V. C. Jordan, M. M. Collins, L. Rowsby, and G. Prestwich (1977). A monohydroxylated metabolite of tamoxifen with potent antiestrogenic activity. J. Endocrinol. 75:305-316.
42. A. S. Levenson, W. H. Catherino, and V. C. Jordan (1997). Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J. Steroid Biochem. Mol. Biol. 60:261-268.
43. A. S. Levenson and V. C. Jordan (1998). The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res. 58: 1872-1875.
44. S. Halamichi, E. Marden, G. Martin, H. Mackey, C. Abbondonza, M. Brown (1993). Estrogen receptor associated proteins: Possible mediators of hormone induced transcription. Science 264:1455-1458.
45. B. Hanstein, R. Eckner, J. DiRenzo, S. Halamichi, H. Liu, B. Searey, R. Kurokawa, and M. Brown (1996). p300 is a component of an estrogen receptor co-activator complex. Proc. Natl. Acad. Sci. U.S.A. 93:11540-11545.
46. C. Baniahmad, Z. Nowaz, A. Banaihmad, M. A. G. Gleeson, M-J. Tsui, B. W. O'Malley (1995). Enhancement of human estrogen receptor activity by SPT6: A potential co-activator. Mol. Endocrinol. 9:34-43.
47. S. A. Onate, S. Y. Tsai, M-J. Tsai, B. W. O'Malley (1995). Sequence and characterization of a coactivitor for the steroid receptor superfamily. Science 270:1354-1357.
48. J. A. Katzenellenbogen, B. W. O'Malley, B.S. Katzenellenbogen (1996). Tripartite steroid receptor pharmocology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol. Endocrinol. 10:119-131.
49. H. Li, and J. D. Chen (1998). The receptor-associated coactivator-3 activated transcription through CREB-binding protein recruitment and autoregulation. J. Biol. Chem. 273: 5948-5954.
50. Y. Kamei, L. Xu, T. Heinzel, J. Torchia, R. Kurokawa, B. Gloss, S. C. Lin, R. A. Heyman, D. W. Rose, C. K. Glass, and M. G. Rosenfeld (1996). A ABP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85:403-414.
51. H. Hong, K. Kohli, A. Trivedi, D. L. Johnson, and M. R. Stallcup (1996). GRIP-1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc. Natl. Acad. Sci. U.S.A. 93:4948-4952.
52. J. J. Voegel, M. J. S. Heine, C. Zechel, P. Chambon, and H. Gronemeyer (1996). TIF2, a 160kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 15:3667-3675.
53. J. Torchia, D. Rose, J. Inostroza, Y. Kamel, S. Westin, C. Glass, and M. Rosenfeld (1997). The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387:677-684.
54. S. L. Anzick, J. Kononen, R. L. Walker, D. O. Azorsa, M. M. Tanner, X-Y. Guan, G. Sauter, O-P. Kallioniemi, J. M. Trent, and P. S. Meltzer (1997). AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965-968.
55. H. Chen, R. J. Lin, R. L. Schiltz, D. Chakravarti, A. Nash, L. Nagy, M. L. Privalsky, Y. Nakatani, and R. M. Evans (1997). Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90:569-580.
56. N. J. McKenna, Z. Nawaz, S. Y. Tsai, M-J. Tsai, and B. W. O'Malley (1998). Distinct steady state nuclear hormone receptor coregulator complexes exist in vivo. Proc. Natl. Acad. Sci. U.S.A. 95:11697-11702.
57. D. M. Heery, E. Kalkhoven, S. Hoare, and M. G. Parker (1997). A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733-736.
58. A. K. Shiau, D. Barstad, P. M. Loria, L. Cheng, P. J. Kushner, D. A. Agard, and G. L. Greene (1998). The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937.
59. R. M. L. Zwijsen, R. S. Buckle, E. M. Hijmans, C. J. M. Loomans, and R. Bernards (1998). Ligand-independent recruitment of steroid receptor coactivators to estrogen recep-tor by cyclin D1. Genes Dev. 12:3488-3498.
60. N. J. McKenna, J. Xu, Z. Nawaz, S. Y. Tsai, M-J. Tsai, and B. W. O'Malley, (1999). Nuclear receptor coactivators: Multiple enzymes, multiple complexes, multiple functions. J. Steroid Biochem. Mol. Biol. 69:3-12.
61. S. J. Bannister and T. Kouzarides (1996). The CBP co-activator is a histone acetyltransferase. Nature 384:641-643.
62. T. E. Spencer, G. Jenster, M. M. Buurcin, C. D. Allis, J. X. Zhou, C. A. Mizzen, N. J. McKenna, S. A. Onate, S. Y. Tsai, M-J. Tsai, and B. W. O'Malley (1997). Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389: 194-198.
63. C. L. Smith, Z. Nawaz, and B. W. O'Malley (1997) Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol 11:693-705.
64. X. Zhang, M. Jeyakumar, S. Petukhov, and M. K. Bagchi (1998). A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol. Endocrinol. 12:513-524.
65. G. S. Takimoto, J. D. Graham, T. A. Jackson, L. Tung, R. L. Powell, L. D. Horwitz, and K. B. Horwitz. Tamoxifen resistant breast cancer: Coregulators determine the direction of transcription by antagonist-occupied steroid receptors. J. Steroid Biochem. Mol. Biol. 69:45-50.
66. M. Berry, D. Metzger, and P. Chambon (1990). Role of the two activating domains of the estrogen receptor in the cell type end promoter context dependent agonist activity of the antioestrogen 4 hydroxytamoxifen EMBO J. 9:2811-2818.
67. D. P. McDonnell, D. L. Clemm, T. Herman, M. E. Goldman, and J. W. Pike (1995). Analysis of estrogen receptor function reveals three distinct classes of antiestrogens. Mol. Endocrinol. 9:659-669.
68. G. G. Kuiper, E. Enmark, M. Pelto-Huikko, S. Nilsson, and J. A. Gustafsson (1996). Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. 93:5925-5930.
69. R. A. Bhat, D. C. Harnish, P. E. Stevis, C. R. Lyttle, and B. S. Komm (1998). A novel human estrogen receptor β: Identification and functional analysis of additional N-terminal amino acids. J. Steroid Biochem. Mol. Biol. 67:233-240.
70. S. Ogawa, S. Inoue, T. Watanabe, H. Hiroi, A. Orimo, T. Hosoi, Y. Ouchi, and M. Muramatsu (1998). Biochem. Biophys. Res. Com. 243:122-126.
71. S. M. Cowley, S. Hoare, S. Mosselman, and M. G. Parker (1997). Estrogen receptors α and β form heterodimers on DNA. J. Biol. Chem. 272:19585-19862.
72. P. Pace, J. Taylor, S. Suntharalingam, R. C. Coombes, and S. Ali (1997). Human estrogen receptor β binds DNA in a manner similar to and dimerizes with estrogen receptor α. J. Biol. Chem. 272:25832-25838.
73. S. M. Hyder, C. Chiappetta, and G. M. Stancel (1999). Interaction of human estrogen receptors α and β with the same naturally occurring estrogen response elements. Biochem. Pharmacol 57:597-601.
74. S. M. Cowley and M. G. Parker (1999). A comparison of transcriptional activation by ERα and ERβ. J. Steroid Biochem. Mol. Biol. 69:165-175.
75. T. Barkhem, B. Carlsson, Y. Nilsson, E. Enmark, J-A. Gustafsson, and S. Nilsson (1998). Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol. Pharmacol. 54:105-112.
76. J. Sun, M. Meyers, B. E. Fink, R. Rajendran, J. Katzenellenbogen, and B. S. Katzenellenbogen (1999). Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-α or estrogen receptor-β. Endocrinology 140: 800-804.
77. P. Webb, G. N. Lopez, R. M. Uht, and P. J. Kushner (1995). Tamoxifen activation of the estrogen receptor/AP-1 Pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endorinol. 9:443-456.
78. K. Paech, P. Webb, G. G. Kuiper, S. Nilsson, J. A. Gustafsson, P. J. Kushner, and J. M. Scarlan (1997). Differential ligand activation of estrogen receptor ERα and ERβ at AP-1 sites. Science 277:1508-1510.
79. V. Speirs, A. T. Parkes, M. J. Kerin, D. S. Walton, P. J. Carleton, J. N. Fox, and S. L. Atkin, (1999). Coexpression of estrogen receptor α and β: Poor prognostic factors in human breast cancer. Cancer Res. 59:525-528.
80. H. Dotzlaw, E. Leygue, P. H. Watson, and L. C. Murphy (1999). Estrogen receptor-β messenger RNA expression in human breast tumor biopsies: Relationship to steroid receptor status and regulation by progestins. Cancer Res. 59:529-532.
81. G. G. Kuiper, B. Carlsson, K. Grnadien, E. Enmark, J. Haggblad, S. Nilsson, and J. A. Gustafsson (1997). Comparison of ligand binding specificity and transcript tissue distribution of estrogen receptor α and β. Endocrinology 138:863-870.
82. E. A. Vladusic, A. E. Hornby, F. K. Guerra-Vladusic, and R. Lupu (1998). Expression of estrogen receptor β messenger RNA variant in breast cancer. Cancer Res. 58: 210-214.
83. E. Leygue, H. Dotzlaw, P. H. Watson, and L. C. Murphy (1999). Expression of estrogen receptor β1, β2, and β5 messenger RNAs in human breast tissue. Cancer Res. 59:1175-1179.
84. B. Hanstein, H. Liu, M. C. Yancisin, and M. Brown (1999). Functional analysis of a novel estrogen receptor-β isoform. Mol. Endocrinol 13:129-137.
85. D. A. Tonetti and V.C. Jordan (1997). The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer. Invited review, J. Steroid. Biochem. Mol. Biol. 62:119-128.
86. Early Breast Cancer Trialists' Collaborative Group (1998). Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351:1451-1467.
87. J. I. MacGregor and V. C. Jordan (1998). Basic guide to the mechanisms of antiestrogen action. Pharm. Rev. 50:151-196.
88. V. C. Jordan, C. J. Dix, and K. E. Allen (1979). The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In S. E. Salmon and S. E. Jones (eds.), Adjuvant Therapy of Cancer II, Grune and Stratton Inc., pp. 19-26.
89. V. C. Jordan and K. E. Allen (1980). Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur. J. Cancer 16:239-251.
90. V. C. Jordan (1983). Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: Problems and potential for future clinical applications. Breast Cancer Res. Treat. 3 (Suppl.): S73-86.
91. B. Fisher, J. P. Costantino, D. L. Wickerham, C. Redmond, M. Kovanah, W. M. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wiend, E. Tan-Chiu, L. Ford, and N. Wolmark (1998). Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90:1371-1388.
92. T. J. Powles, J. R. Hardy, S. E. Ashley, G. M. Farrington, D. Cosgrove, J. B. Dovey, M. Dowsett, J. A. McKinna, A. G. Nash, H. D. Sinnett, C. R. Tillyer, J. G. Treleaven (1989). A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Brit. J. Cancer 60:126-133.
93. U. Veronesi, P. Maisonneuve, and A. Costa (1998). Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomized trial among hysterectomized women. Lancet 362:93-97.
94. M. H. Gail, L. A. Brinton, and D. P. Byar (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl. Cancer Inst. 81:1879-1886.
95. T. J. Powles, R. Eeles, S. E. Ashley, D. Easton, J. Chang, M. Dowsett, V. A. Tidy, J. Viggers, J. B. Davey (1998). Interim analysis of the incident breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 362:98-101.
96. C. D. Jones, M. G. Jevnikar, A. J. Pike, M. K. Peters, L. J. Black, A. R. Thompson, J. F. Falcone, and J. A. Clemens (1984). Antiestrogens 2 Structure-activity studies in a series of 3 aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydrotyphenyl) benzo[b] thiene-3-yl] [4-[2-(1-piperidinyl) ethoxy]-phenyl] methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal estrogenicity. J. Med. Chem. 27:1057-1066.
97. A. U. Buzdar, C. Marcus, F. Holmes, V. Hug, and G. Hortobagyi (1988). Phase II evaluation of LY156758 in metastatic breast cancer. Oncology 45:344-345.
98. W. J. Gradishar, J. E. Glusman, C. L. Vogel, J. L. Mansi, N. S. A. Stuart, J. Carmichael, D. Elling, K. R. Kunz, G. W. Sledge (1997). Raloxifene HCl a new endocrine agent is active in estrogen receptor positive metastatic breast cancer. Breast Cancer Res. Treat. 46:53 Abstract #209.
99. J. A. Clemens, D. R. Bennett, L. J. Black, and C. D. Jones (1983). Effects of new antiestrogen keoxifene LY156758 on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci. 32:2868-2875.
100. M. A. Anzano, C. W. Peer, J. M. Smith, L. T. Mullen, M. W. Shrader, D. L. Logsdon, C. L. Driver, C. C. Brauen, A. B. Robert, and M. B. Sporn (1996). Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid. J. Natl. Cancer Inst. 88:123-125.
101. L. J. Lerner and V. C. Jordan (1990). Development of antiestrogens and their use in breast cancer. B.F. Cain Memorial Lecture. Cancer Res. 50:4177-4189.
102. S. R. Cummings, S. Eckert, K. A. Krueger, D. Grady, T. J. Powles, J. A. Cauley, L. Norton, T. Nickelsen, N. H. Bjarnason, M. Morrow, M. E. Lippman, D. Black, J. E. Glusman, A. Costa, and V. C. Jordan (1999). The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189-2197.
103. V. C. Jordan, J. E. Glusman, S. Eckert, M. E. Lippman, T. J. Powles, A. Costa, M. Morrow, and L. Norton (1998). Raloxifene reduces incident primary breast cancers. Intergrated data from multicenter double blind, placebo controlled randomized trials in postmenopausal women. Breast Cancer Res. Treat. 50:227 Abstract #2.
104. A. Lacassagne (1936). Hormonal pathogenesis of adenocarcinoma of the breast. Am J. Cancer 27:217.
105. M. B. Sporn (1976). Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res. 36:2699-2702.
106. V. C. Jordan (1988). Chemosuppression of breast cancer with tamoxifen: Laboratory evidence and future clinical investigations. Cancer Invest. 6:589-595.